The China National Medical Products Administration (NMPA) has granted priority review for Innovent Biologics and Hutchmed’s new drug application (NDA) for the combination of sintilimab and fruquintinib for advanced endometrial cancer.

The NDA seeks a new therapeutic regimen for people with proficient mismatch repair or non-microsatellite instability-high tumours who have exhausted previous systemic therapies and are not eligible for curative surgical procedures or radiation.

Sintilimab is a programmed cell death protein 1 immunoglobulin G4 monoclonal antibody, marketed in China as TYVYT (sintilimab injection). It has been developed through a collaboration between Innovent and Eli Lilly.

The application is based on the data from the FRUSICA-1 study, a Phase II multicentre, open-label trial.

The primary measure of success was the objective response rate as assessed by an independent review committee.

Disease control rate, duration of response, progression-free survival, overall survival and pharmacokinetic assessments were the secondary endpoints.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In July 2023, the NMPA recognised the potential of the combination therapy, granting it a breakthrough designation. This status is reserved for treatments that offer a significant advancement over existing options for serious ailments lacking effective therapies, and where clinical evidence indicates substantial benefits.

Innovent senior vice-president Dr Hui Zhou stated: “TYVYT (sintilimab injection), as a backbone therapy in immuno-oncology, in combination with an anti-angiogenetic drug, may improve the prognosis for endometrial cancer patients in China.

“We are excited about the NDA acceptance and priority review designation, which increases our potential to bring a new treatment option to endometrial cancer patients, and concurrently strengthens the leadership position of TYVYTin China.”

In August 2023, the company received approval from China NMPA for SINTBILO (tafolecimab injection) for primary hypercholesterolemia and mixed dyslipidemia.